about
msPurity: Automated Evaluation of Precursor Ion Purity for Mass Spectrometry-Based Fragmentation in Metabolomics.Use of a pre-analysis osmolality normalisation method to correct for variable urine concentrations and for improved metabolomic analyses.Nanoflow-Nanospray Mass Spectrometry Metabolomics Reveals Disruption of the Urinary Metabolite Profiles of HIV-Positive Patients on Combination Antiretroviral Therapy.Current Application of Capillary Electrophoresis in Nanomaterial Characterisation and Its Potential to Characterise the Protein and Small Molecule Corona.A review of nanoscale LC-ESI for metabolomics and its potential to enhance the metabolome coverage.Collection and Preparation of Clinical Samples for Metabolomics.Evaluation of analytical performance and reliability of direct nanoLC-nanoESI-high resolution mass spectrometry for profiling the (xeno)metabolomeCorona Isolation Method Matters: Capillary Electrophoresis Mass Spectrometry Based Comparison of Protein Corona Compositions Following On-Particle versus In-Solution or In-Gel DigestionSurface Chemistry-Dependent Evolution of the Nanomaterial Corona on TiO2 Nanomaterials Following Uptake and Sub-Cellular LocalizationFast and Robust Proteome Screening Platform Identifies Neutrophil Extracellular Trap Formation in the Lung in Response to Cobalt Ferrite NanoparticlesQuantitative Lipoprotein Subclass and Low Molecular Weight Metabolite Analysis in Human Serum and Plasma by 1H NMR Spectroscopy in a Multilaboratory TrialThe Nanomaterial Metabolite Corona Determined Using a Quantitative Metabolomics Approach: A Pilot StudyOn the issue of transparency and reproducibility in nanomedicineThe potential of nanoflow liquid chromatography-nano electrospray ionisation-mass spectrometry for global profiling the faecal metabolomePublisher Correction: On the issue of transparency and reproducibility in nanomedicineDeciphering the particle specific effects on metabolism in rat liver and plasma from ZnO nanoparticles versus ionic Zn exposure
P50
Q36279588-CC45C951-0204-4344-99F4-77F34FE9AFD7Q38922049-6AE4DDB3-AB56-490E-BC26-70A165667B18Q39463277-BF4D8ECC-5892-4031-B240-7C6D3EB6C7F2Q50034205-AE70B665-5DC7-43CF-8F2C-712C46840226Q52676048-377A6C6D-473A-4594-9623-81150939BD8AQ52736868-0FB2FE06-F517-4DA3-90B2-4B9FA5D9DDE7Q60482313-58F235D5-0E2D-4C82-A65B-A06DEDED73C2Q70203045-884CB69C-0EE3-4136-A142-B3EAFCF1343DQ89919852-0C4DD995-02CB-4E8B-8AAF-B6B43DADA8F7Q90294062-1E91B1BE-B8A4-4DB3-B025-3C59DE9415CCQ91423364-44F9887F-ACFD-4BE2-AC72-0576692AB32EQ91510876-0973E727-031E-4A1A-81FB-471E95B0AFB8Q91595253-F82B7157-4A8B-4E82-893D-79E7B532AD29Q91705161-8EFCD674-0379-4F1C-BE2D-489000DD79B8Q91755217-7A2C4CA9-919B-4965-8ADC-31D4D3A5C711Q92280646-97FC5A79-0A0C-4350-9BF9-68FDEE1A1848
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Andrew J Chetwynd
@ast
Andrew J Chetwynd
@en
Andrew J Chetwynd
@es
Andrew J Chetwynd
@nl
type
label
Andrew J Chetwynd
@ast
Andrew J Chetwynd
@en
Andrew J Chetwynd
@es
Andrew J Chetwynd
@nl
prefLabel
Andrew J Chetwynd
@ast
Andrew J Chetwynd
@en
Andrew J Chetwynd
@es
Andrew J Chetwynd
@nl
P106
P1153
56406310900
P21
P31
P4012
P496
0000-0001-6648-6881